This case report highlights the risk of subacute doxorubicin-induced cardiomyopathy in patients receiving adriamycin for malignancies, even in the absence of traditional cardiac risk factors.
May warrant monitoring for doxorubicin cardiomyopathy in Hodgkin lymphoma without risk factors; leaves open incidence and prevention in prospective studies.
Adriamycin is an antineoplastic agent used in a wide variety of malignancies. Its use is limited because of a cumulative, dose-dependent irreversible cardiomyopathy. We report a case of adriamycin-induced cardiomyopathy, after he had undergone chemotherapy for Hodgin lymphoma. The patient had no cardiac risk factors, and neither laboratory nor imaging findings suggested myocarditis or dilated cardiomyopathy. Echocardiographic findings and differential diagnosis led us to attribute his condition to subacute doxorubicin-induced cardiomyopathy. J Med Cases. 2015;6(5):226-228 doi: http://dx.doi.org/10.14740/jmc2132w
No takes yet. Share an insight, caveat, or question.
Marios Lemoniatis (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: